Is Black Diamond Therapeutics Inc halal to invest in?

According to Musaffa's Shariah screening methodology, Black Diamond Therapeutics Inc (BDTX) is currently classified as NOT HALAL as of March 2026. The classification is based on an evaluation of the company's business activities and financial ratios to determine whether it meets Islamic investment guidelines.

Is Black Diamond Therapeutics Inc a Shariah-compliant stock?

A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Black Diamond Therapeutics Inc using these criteria to determine its compliance status.

Can Muslims buy shares of Black Diamond Therapeutics Inc?

Muslim investors may consider investing in Black Diamond Therapeutics Inc if it meets Shariah compliance standards. Investors typically review the company's business activities, debt levels, and non-permissible income before making a decision.

Why is Black Diamond Therapeutics Inc classified as NOT HALAL?

Musaffa determines the Shariah status of Black Diamond Therapeutics Inc by analyzing whether the company's core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.

How often is the Shariah compliance for Black Diamond Therapeutics Inc updated?

The Shariah compliance status of Black Diamond Therapeutics Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.

Can a halal stock like Black Diamond Therapeutics Inc become non-compliant?

Yes. A stock that is currently Shariah-compliant may become non-compliant if the company's financial ratios exceed Shariah thresholds or its business activities change.

Where can I check the Shariah status of Black Diamond Therapeutics Inc?

You can check the latest Shariah compliance status of Black Diamond Therapeutics Inc on Musaffa's stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.

BDTX Shariah Compliance

Screening Methodology: AAOIFI

NOT HALAL

Last Updated: March 18, 2026

Report Source: 2025 Annual Report

Black Diamond Therapeutics Inc. Stock Analysis BDTX

United States Health Care Micro Cap Report: 2025 Annual

Black Diamond Therapeutics, Inc. is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The company is headquartered in Cambridge, Massachusetts and currently employs 21 full-time employees. The company went IPO on 2020-01-30. The Company’s MasterKey therapies are designed to address a broad spectrum of genetically defined tumors, overcome resistance, minimize wild-type mediated toxicities, and be brain penetrant to treat central nervous system disease. The firm is advancing a Phase 2 NSCLC trial of BDTX-1535, a brain-penetrant fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor targeting EGFR-mutant NSCLC and glioblastoma. Its BDTX-4933 pipeline product is out-licensed to Servier. BDTX-4933 is designed to target RAS and RAF alterations in solid tumors. The company is exploring partnership opportunities for its FGFR2/3 selective development candidate BDTX-4876.

Key Statistics of Black Diamond Therapeutics Inc (BDTX)

Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.

Today's Range

$2.70$2.84

Today's Open

$2.82

Volume

626.39K

P/E Ratio (TTM)

7.05

52 Week Range

$1.77$4.94

Market Cap

164.42M

Avg. Volume

905.70K

Dividend Yield

Financial Metrics & Statements of Black Diamond Therapeutics Inc (BDTX)

FAQ's for Black Diamond Therapeutics Inc (BDTX)

According to Musaffa’s Shariah screening methodology, Black Diamond Therapeutics Inc (BDTX) is currently classified as NOT HALAL as of March 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.